ATARA BIOTHERAPEUTICS, INC. Asset Retirement Obligation, Accretion Expense
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Asset Retirement Obligation, Accretion Expense of $87.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AssetRetirementObligationAccretionExpense · last filed 2022-02-28
- ATARA BIOTHERAPEUTICS, INC. asset retirement obligation, accretion expense for the quarter ending 2019-12-31 was $18.00K, a 5.88% increase year-over-year.
- ATARA BIOTHERAPEUTICS, INC. asset retirement obligation, accretion expense for the quarter ending 2019-09-30 was $18.00K, a 12.50% increase year-over-year.
- ATARA BIOTHERAPEUTICS, INC. asset retirement obligation, accretion expense for the quarter ending 2019-06-30 was $18.00K.
- ATARA BIOTHERAPEUTICS, INC. asset retirement obligation, accretion expense for the quarter ending 2019-03-31 was $17.00K.
- ATARA BIOTHERAPEUTICS, INC. asset retirement obligation, accretion expense for fiscal 2021 was $87.00K, a 11.54% increase from fiscal 2020.
- ATARA BIOTHERAPEUTICS, INC. asset retirement obligation, accretion expense for fiscal 2020 was $78.00K, a 9.86% increase from fiscal 2019.
- ATARA BIOTHERAPEUTICS, INC. asset retirement obligation, accretion expense for fiscal 2019 was $71.00K, a 44.90% increase from fiscal 2018.
- ATARA BIOTHERAPEUTICS, INC. asset retirement obligation, accretion expense for fiscal 2018 was $49.00K.
| Period end | Asset Retirement Obligation, Accretion Expense 3 month | Asset Retirement Obligation, Accretion Expense 6 month | Asset Retirement Obligation, Accretion Expense 9 month | Asset Retirement Obligation, Accretion Expense 12 month |
|---|---|---|---|---|
| 2021-12-31 | $87.00K 10-K · filed 2022-02-28 | |||
| 2020-12-31 | $78.00K 10-K · filed 2021-03-01 | |||
| 2019-12-31 | $18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $36.00K derived: sum of 2 quarters · filed 2020-02-27 | $54.00K derived: sum of 3 quarters · filed 2020-02-27 | $71.00K 10-K · filed 2020-02-27 |
| 2019-09-30 | $18.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $36.00K derived: sum of 2 quarters · filed 2019-11-07 | $53.00K 10-Q · filed 2019-11-07 | $70.00K derived: sum of 4 quarters · filed 2019-11-07 |
| 2019-06-30 | $18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $35.00K 10-Q · filed 2019-08-08 | $52.00K derived: sum of 3 quarters · filed 2019-08-08 | $68.00K derived: sum of 4 quarters · filed 2019-08-08 |
| 2019-03-31 | $17.00K 10-Q · filed 2019-05-09 | $34.00K derived: sum of 2 quarters · filed 2019-05-09 | $50.00K derived: sum of 3 quarters · filed 2019-05-09 | |
| 2018-12-31 | $17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $33.00K derived: sum of 2 quarters · filed 2019-02-26 | $49.00K 10-K · filed 2019-02-26 | |
| 2018-09-30 | $16.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $32.00K 10-Q · filed 2018-11-06 | ||
| 2018-06-30 | $16.00K 10-Q · filed 2018-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |